AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17026510 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated professional tooth cleaning combined with oral hygiene instruction
Number of subjects: 12
Study 17026510 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene instruction only (Control)
Number of subjects: 12
Study 14629059 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 15
Study 14629059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 15
Study 14629059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (higher dose)
Number of subjects: 15
Study 14629059 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic infiltration
Number of subjects: 15
Study 10930965 — intervention group
Group type: EXPERIMENTAL
Intervention: Final pharmacostatistical model for lamotrigine
Number of subjects: 0
Study 10930965 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-inducing antiepileptic drugs without valproate
Number of subjects: 0
Study 10930965 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight as a covariate
Number of subjects: 0
Study 10930965 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex effect on clearance
Number of subjects: 0
Study 7642042 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. atenolol
Number of subjects: 12377
Study 7642042 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (SK)
Number of subjects: 12377
Study 7642042 — intervention group
Group type: COMPARATOR
Intervention: rtPA
Number of subjects: 12377
Study 7642042 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 12377
Study 2504972 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifurol (6-12 mg/kg/day) + MMC (0.2 mg/kg x 2)
Number of subjects: 0
Study 2504972 — intervention group
Group type: COMPARATOR
Intervention: Tegafur (12 mg/kg/day) + MMC (0.2 mg/kg x 2)
Number of subjects: 0
Study 969779 — intervention group
Group type: EXPERIMENTAL
Intervention: Choleretics administered orally in a dosage two to five times more than the recommended one
Number of subjects: 0
Study 969779 — intervention group
Group type: COMPARATOR
Intervention: Standardized secretion‐stimulation (dehydrocholic acid, i.v., taurocholic acid intraduodenally, secretin i.v., meals)
Number of subjects: 0
Study 31725115 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (IIV4)
Number of subjects: 12018
Study 31725115 — intervention group
Group type: COMPARATOR
Intervention: Control vaccines
Number of subjects: 12018
Study 30422319 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant with midazolam
Number of subjects: 0
Study 30422319 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant with ketoconazole
Number of subjects: 0
Study 30422319 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant with rifampin
Number of subjects: 0
Study 28234235 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor monotherapy (PI‐mono)
Number of subjects: 16
Study 28234235 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 16
Study 26136404 — intervention group
Group type: EXPERIMENTAL
Intervention: Families Taking Control (FTC)
Number of subjects: 83
Study 26136404 — intervention group
Group type: COMPARATOR
Intervention: Delayed Intervention Control (DIC)
Number of subjects: 83
Study 25065540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 24
Study 25065540 — intervention group
Group type: COMPARATOR
Intervention: Chest Physical Therapy (CPT)
Number of subjects: 24
Study 22791766 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent PTH(1-84) and ibandronate for 6 months followed by 18 months of ibandronate
Number of subjects: 44
Study 22791766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential PTH(1-84) for two courses of 3 months followed by 9 months of ibandronate
Number of subjects: 44
Study 22791766 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent PTH(1-84) and ibandronate
Number of subjects: 44
Study 22791766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential PTH(1-84)
Number of subjects: 44
Study 22791766 — intervention group
Group type: COMPARATOR
Intervention: Concurrent and sequential therapies
Number of subjects: 44
Study 19354091 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Restoration (FR) treatment group
Number of subjects: 66
Study 19354091 — intervention group
Group type: COMPARATOR
Intervention: Standard anesthesia pain clinic treatment comparison group
Number of subjects: 66
Study 17586184 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 420
Study 17586184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 15642679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypobaric hypoxia (IHH)
Number of subjects: 0
Study 15642679 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 15463835 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin nebuliser solution (TNS)
Number of subjects: 115
Study 15463835 — intervention group
Group type: COMPARATOR
Intervention: Nebulised colistin
Number of subjects: 115
Study 9818296 — intervention group
Group type: EXPERIMENTAL
Intervention: Acenocoumarol once daily
Number of subjects: 12
Study 9818296 — intervention group
Group type: COMPARATOR
Intervention: Acenocoumarol twice daily
Number of subjects: 12
Study 8950783 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms recombinant human (rh) IL‐6
Number of subjects: 8
Study 8950783 — intervention group
Group type: COMPARATOR
Intervention: Saline (control study)
Number of subjects: 8
Study 1827042 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril 2.5 mg
Number of subjects: 86
Study 1827042 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide 25 mg
Number of subjects: 86
Study 1827042 — intervention group
Group type: EXPERIMENTAL
Intervention: isosorbide‐5‐mononitrate (ISMN) 20 mg
Number of subjects: 86
Study 1827042 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 86
Study 7136568 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm immobilization in pronation
Number of subjects: 42
Study 7136568 — intervention group
Group type: COMPARATOR
Intervention: Forearm immobilization in supination
Number of subjects: 42
Study 30646822 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically instrumented T2D
Number of subjects: 318664
Study 30646822 — intervention group
Group type: COMPARATOR
Intervention: Genetically determined hypertension
Number of subjects: 318664
Study 30646822 — intervention group
Group type: COMPARATOR
Intervention: Elevated systolic BP or diastolic BP
Number of subjects: 318664
Study 30646822 — intervention group
Group type: COMPARATOR
Intervention: Hypertension→T2D relation
Number of subjects: 318664
Study 30646822 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D→hypertension relation
Number of subjects: 318664
Study 28240765 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD <0.1% after first induction course
Number of subjects: 142
Study 28240765 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD 0.1-1% after first induction course
Number of subjects: 142
Study 28240765 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD >/=1% after first induction course
Number of subjects: 142
Study 28240765 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD >/=0.1% after first induction course, followed by MRD <0.1% after second induction course
Number of subjects: 142
Study 28240765 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD >/=0.1% after first induction course, persisting MRD >/=0.1% after second induction course
Number of subjects: 142
Study 25828636 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of irbesartan/hydrochlorothiazide FDC tablet (300/12.5 mg)
Number of subjects: 24
Study 25828636 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of irbesartan/hydrochlorothiazide FDC tablet (300/12.5 mg)
Number of subjects: 24
Study 24755244 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure drainage (group B)
Number of subjects: 18
Study 24755244 — intervention group
Group type: COMPARATOR
Intervention: No drainage (group A)
Number of subjects: 18
Study 24755244 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure drainage (group B) and 4 h clamping drainage (group C)
Number of subjects: 18
Study 24755244 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 18
Study 21175274 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-led titration of insulin glargine
Number of subjects: 0
Study 21175274 — intervention group
Group type: COMPARATOR
Intervention: Physician-led titration of insulin glargine
Number of subjects: 0
Study 19362705 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 39
Study 19362705 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 39
Study 17804843 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg twice daily
Number of subjects: 1237
Study 17804843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1237
Study 15108766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 63
Study 15108766 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (FK506)
Number of subjects: 63
Study 15108766 — intervention group
Group type: EXPERIMENTAL
Intervention: Banff acute rejection (AR) grade >= 1A
Number of subjects: 63
Study 15108766 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical AR prior to day 50 biopsy
Number of subjects: 63
Study 15108766 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased tubulointerstitial CD68-positive cells
Number of subjects: 63
Study 11411908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 72
Study 11411908 — intervention group
Group type: COMPARATOR
Intervention: UVAB phototherapy
Number of subjects: 72
Study 9749453 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-parametric covariance analysis
Number of subjects: 0
Study 9749453 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical model for postulated sampling process
Number of subjects: 0
Study 9749453 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-parametric methods
Number of subjects: 0
Study 9749453 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted least squares application
Number of subjects: 0
Study 9749453 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical model for dichotomous or ordered categories
Number of subjects: 0
Study 9749453 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative methods for covariance analysis
Number of subjects: 0
Study 7631727 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective low-forceps delivery
Number of subjects: 50
Study 7631727 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous delivery
Number of subjects: 50
Study 2604532 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical Tetracoq vaccine
Number of subjects: 249
Study 2604532 — intervention group
Group type: COMPARATOR
Intervention: Inactivated poliomyelitis vaccines prepared on monkey kidney cells
Number of subjects: 249
Study 2604532 — intervention group
Group type: COMPARATOR
Intervention: Inactivated poliomyelitis vaccines prepared on Vero-type continuous cell lines
Number of subjects: 249
Study 2604532 — intervention group
Group type: COMPARATOR
Intervention: Polio vaccine placed in a 2-compartment syringe separating the polio vaccine from the DPT
Number of subjects: 249
Study 1234488 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate syrup, B.P.C.
Number of subjects: 6
Study 1234488 — intervention group
Group type: COMPARATOR
Intervention: Syrup alone
Number of subjects: 6
Study 31448116 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA (saturated fatty acids)
Number of subjects: 27
Study 31448116 — intervention group
Group type: COMPARATOR
Intervention: n-6 PUFA (polyunsaturated fatty acids)
Number of subjects: 27
Study 28162906 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary stent placement with iodine-125 (125I) seeds (group A)
Number of subjects: 55
Study 28162906 — intervention group
Group type: COMPARATOR
Intervention: Biliary stent only (group B)
Number of subjects: 55
Study 26576178 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day plus Zn sulfate (50 mg elemental Zn three times a day)
Number of subjects: 30
Study 26576178 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 6 mg/day plus placebo
Number of subjects: 30
Study 24266299 — intervention group
Group type: EXPERIMENTAL
Intervention: Holdex tube holder
Number of subjects: 60
Study 24266299 — intervention group
Group type: COMPARATOR
Intervention: BD Vacutainer One Use Holder
Number of subjects: 60
Study 21410733 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1386 30 mg
Number of subjects: 22
Study 21410733 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1386 95 mg
Number of subjects: 22
Study 21410733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 18820505 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-session curriculum emphasizing LC critical decisions and error prevention
Number of subjects: 0
Study 18820505 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 17217713 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang 0.6 g Bid
Number of subjects: 4870
Study 17217713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4870
Study 14633563 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL dilute solution (0.1%/0.5 microg/mL ropivacaine/fentanyl)
Number of subjects: 150
Study 14633563 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mL concentrated solution
Number of subjects: 150
Study 14633563 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mL ropivacaine and 6 microg fentanyl
Number of subjects: 150
Study 11084114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular resynchronization therapy (VRT) by left or biventricular stimulation
Number of subjects: 64
Study 9084896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 9084896 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 0
Study 9084896 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine and Maprotiline
Number of subjects: 0
Study 8409177 — intervention group
Group type: EXPERIMENTAL
Intervention: Terodiline
Number of subjects: 98
Study 8409177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 3548983 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 30
Study 3548983 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 30
Study 31308644 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral medicine intervention in physical therapy (BMPI)
Number of subjects: 105
Study 31308644 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 105
Study 30261738 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Number of subjects: 90
Study 30261738 — intervention group
Group type: COMPARATOR
Intervention: Sputum AFB smear
Number of subjects: 90
Study 27769710 — intervention group
Group type: COMPARATOR
Intervention: 8-oxo-2′-deoxyguanosine (8-oxo-dG)
Number of subjects: 0
Study 27769710 — intervention group
Group type: COMPARATOR
Intervention: (5′S)-8,5′-cyclo-2′-deoxyadenosine (S-cdA)
Number of subjects: 0
Study 27769710 — intervention group
Group type: COMPARATOR
Intervention: 8-iso-prostaglandin F2α (8-iso-PGF2α)
Number of subjects: 0
Study 27769710 — intervention group
Group type: COMPARATOR
Intervention: (5′R)-8,5′-cyclo-2′-deoxyadenosine (R-cdA)
Number of subjects: 0
Study 27769710 — intervention group
Group type: COMPARATOR
Intervention: HbA1c
Number of subjects: 0
Study 25415733 — intervention group
Group type: COMPARATOR
Intervention: Regular dose (CTDIvol, 38.4 mGy)
Number of subjects: 37
Study 25415733 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose (CTDIvol, 24.6 mGy) with 30% ASIR
Number of subjects: 37
Study 25415733 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose (CTDIvol, 15.4 mGy) with 50% ASIR
Number of subjects: 37
Study 25415733 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased ASIR percentages (70% and 90%)
Number of subjects: 37
Study 25415733 — intervention group
Group type: EXPERIMENTAL
Intervention: All ASIR percentages regardless of radiation dose
Number of subjects: 37
Study 22805387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime/heparin lock
Number of subjects: 82
Study 22805387 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin lock
Number of subjects: 82
Study 20803153 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory warm-up (RWU)
Number of subjects: 9
Study 19124398 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (20-40 mg/day)
Number of subjects: 165
Study 19124398 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50-100 mg/day)
Number of subjects: 165
Study 16380885 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Refractor (neutral)
Number of subjects: 150
Study 16380885 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Refractor (cyclo)
Number of subjects: 150
Study 16380885 — intervention group
Group type: EXPERIMENTAL
Intervention: RK-5 (Canon)
Number of subjects: 150
Study 16380885 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinomax K-plus (Nikon)
Number of subjects: 150
Study 12087569 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly epoetin beta (n = 84)
Number of subjects: 173
Study 12087569 — intervention group
Group type: COMPARATOR
Intervention: Thrice-weekly epoetin beta (n = 89)
Number of subjects: 173
Study 9451066 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (1 x 10(6) kallikrein activation units)
Number of subjects: 50
Study 9451066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7753541 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary (<24 h) reamed nailing of femur shaft fracture in multiple trauma patients with thoracic trauma
Number of subjects: 766
Study 7753541 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral reaming
Number of subjects: 766
Study 7753541 — intervention group
Group type: COMPARATOR
Intervention: Unreamed femur nailing
Number of subjects: 766
Study 2527473 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (150 mg/day)
Number of subjects: 9
Study 2527473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (15 mg/day)
Number of subjects: 9
Study 2527473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31943297 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFNÎ± treatment for 48 weeks plus 24 weeks follow-up
Number of subjects: 1623
Study 31943297 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic score (PGS) integrating CFB rs12614 and STAT4 rs7574865
Number of subjects: 1623
Study 31943297 — intervention group
Group type: COMPARATOR
Intervention: NUCs treatment for 104 weeks
Number of subjects: 1623
Study 29273897 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring
Number of subjects: 161
Study 29273897 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of capillary blood glucose (control)
Number of subjects: 161
Study 28167468 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intravenous nutrition therapy (Group A)
Number of subjects: 80
Study 28167468 — intervention group
Group type: COMPARATOR
Intervention: Late parenteral nutrition (Group B)
Number of subjects: 80
Study 25655828 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS device (TANYX®) applied at 85 Hz frequency for 30 minutes at eight-hour intervals for up to seven days.
Number of subjects: 40
Study 25655828 — intervention group
Group type: COMPARATOR
Intervention: Sham device (placebo group).
Number of subjects: 40
Study 23672269 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg once daily at bedtime (qhs)
Number of subjects: 542
Study 23672269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study 21159785 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (3.0 g eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) at a 5:1 ratio)
Number of subjects: 128
Study 21159785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 18224442 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen 500 mg twice daily plus omeprazole 20 mg daily
Number of subjects: 70
Study 18224442 — intervention group
Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily plus placebo
Number of subjects: 70
Study 17068673 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal vibroacoustic stimulation
Number of subjects: 72
Study 17068673 — intervention group
Group type: COMPARATOR
Intervention: Control (no fetal stimulation)
Number of subjects: 72
Study 12643886 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 682
Study 12643886 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 682
Study 12643886 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Atenolol and Nifedipine
Number of subjects: 682
Study 12643886 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 682
Study 10676687 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.1 mg b.i.d. (initial dose), increased weekly to 0.2 mg and 0.3 mg b.i.d. as target doses.
Number of subjects: 97
Study 10676687 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (0.1, 0.2, or 0.3 mg b.i.d.)
Number of subjects: 97
Study 10676687 — intervention group
Group type: COMPARATOR
Intervention: Moxonidine and placebo
Number of subjects: 97
Study 9511686 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal group sessions on position and attachment of the baby on the breast conducted by a lactation consultant
Number of subjects: 70
Study 9511686 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antenatal teaching session)
Number of subjects: 70
Study 9511686 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal group sessions on position and attachment of the baby on the breast
Number of subjects: 70
Study 8452172 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fleroxacin, 400 mg once a day for 4-21 days
Number of subjects: 113